Atossa Genetics Shares Surge Post Announcing Successful Completion and Final Results from Male Phase 1 Study of Topical Endoxifen

By John F. Heerdink, Jr.
Shares of Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, are surging today up over 50% at $1.88 as they reported final results from its Phase 1 dose-escalation study of its proprietary topical Endoxifen in male subjects. Atossa reported preliminary results from this study on September 13, 2018, and those results are now final. All objectives were successfully met.
The Maxim Group’s biotech analyst Jason McCarthy, Ph.D. updated coverage and maintained his $5 Target price.
Learn more about Atossa and keep up with their updates at Vista Partners Dedicated Coverage Page!

Atossa Genetics Announces Successful Completion and Final Results from Male Phase 1 Study of Topical Endoxifen
Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, reported final results from its Phase 1 dose-escalation study of its proprietary topical Endoxifen in male subjects. Atossa.. finance.yahoo.com
Read Full Article


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us